Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells

Cell Death and Disease

Volumn 3, Issue 7, 2012, Pages

  Kawabata, S ^a   Gills, J J ^a   Mercado Matos, J R ^a   LoPiccolo, J ^a   Wilson Iii, W ^a   Hollander, M C ^a   Dennis, P A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

bortezomib; ER stress; lung cancer; nelfinavir; proteotoxicity

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; BORTEZOMIB; CASPASE 3; CASPASE 4; CCAAT ENHANCER BINDING PROTEIN; CYCLOHEXIMIDE; DOUBLE STRANDED RNA; NELFINAVIR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE; SMALL INTERFERING RNA; UBIQUITINATED PROTEIN; X BOX BINDING PROTEIN 1; ATF3 PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; CASPASE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; HUMANS; MICE; MICE, NUDE; MULTIPLE MYELOMA; NELFINAVIR; PROTEASE INHIBITORS; PYRAZINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84864886676     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.87     Document Type: Article

References (36)

1. Hightower L.E. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991; 66: 191-197.
2. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-991.
3. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002; 110: 1383-1388.
4. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011; 13: 184-190.
5. Ma Y, Hendershot L.M. ER chaperone functions during normal and stress conditions. J Chem Neuroanat 2004; 28: 51-65.
6. Grant S. Enhancing proteotoxic stress as an anticancer strategy. Oncotarget 2011; 2: 284-286.
7. Crawford LJ, Walker B, Irvine A.E. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011; 5: 101-110.
8. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510-11519.
9. Mimnaugh EG, Xu W, Vos M, Yuan X, Neckers L. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res 2006; 4: 667-681.
10. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Smallmolecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567-8572.
11. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773-3781.
12. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009; 106: 2200-2205.
13. Schewe DM, Aguirre-Ghiso J.A. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 2009; 69: 1545-1552.
14. Chow WA, Jiang C, Guan M Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009; 10: 61-71.
15. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13: 5183-5194.
16. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11: 381-389.
17. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001; 21: 1249-1259.
18. Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S et al. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res 2008; 68: 5335-5344.
19. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto K.M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008; 68: 2557-2560.
20. Orlowski RZ, Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-1657.
21. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145-156.
22. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489-2499.
23. Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, Schmitz I et al. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 2011; 286: 17682-17692.
24. Bruning A, Vogel M, Mylonas I, Friese K, Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets 2011; 11: 799-809.
25. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009; 4: 87-92.
26. Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R et al. Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer 2011; 71: 283-290.
27. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN Jr, Vokes EE et al. Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). J Thorac Oncol 2011; 6: 1741-1745.
28. Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH et al. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res 2008; 68: 2820-2830.
29. Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleeft H et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther 2008; 7: 1940-1948.
30. Mann MJ, Hendershot L.M. UPR activation alters chemosensitivity of tumor cells. Cancer Biol Ther 2006; 5: 736-740.
31. Taketani K, Kawauchi J, Tanaka-Okamoto M, Ishizaki H, Tanaka Y, Sakai T et al. Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells. Oncogene 2012; 31: 2210-2221.
32. Tian X, Ye J, Alonso-Basanta M, Hahn SM, Koumenis C, Dorsey J.F. Modulation of chopdependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2011; 286: 29408-29416.
33. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP et al. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 2004; 24: 1365-1377.
34. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-490.
35. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
36. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.